Nesiritide Acetate (BNP-32)

Details:

99% purity Nesiritide Acetate (BNP-32) CAS 114471-18-0 For body supplements
 
Nesiritide Acetate (BNP-32)
Cas No.:114471-18-0
Molecular Formula:C143H244N50O42 S4
Molecular Weight:3464.04
Purity (HPLC):97.0%min.
Appearance:White powder
Single Impurity(HPLC):1.0%max
Amino Acid Composition:±10% of theoretical
Peptide Content(N%):≥78.0%
Water Content(Karl Fischer):≤6.0%
Acetate Content(HPIC):≤15.0%
MS(ESI)  Consistent
Mass Balance:95.0~105.0%
 
Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
Teriparatide is a recombinant form of parathyroid hormone consisting of the first (N-terminus) 34 amino acids, which is the bioactive portion of the hormone. It is an effective anabolic (i.e., bone growing) agent used in the treatment of some forms of osteoporosis.It is also occasionally used off-label to speed fracture healing. Teriparatide is identical to a portion of human parathyroid hormone (PTH) and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone.

Products

Our Lab

Freight